Fig. 4.

Effect of DBPR114 and sorafenib on growth and body weight changes in human HCC xenograft tumors. A Antitumor efficacy and B body weight changes from baseline (%). Tumor-bearing animals were randomized; treatment began when the mean tumor volume reached 150 mm³. DBPR114 was administered intravenously at 40 mg/kg once a week. Sorafenib was administered at 30 mg/kg once a day, 5 days per week by oral gavage for 3–6 weeks depending on the individual tumor growth rate of each model. Mean ± SEM, n = 7 mice per group for Hep3B and PLC/PRF/5, n = 8 mice per group for Huh7, and n = 12 mice per group for H22T/VGH mice. *p < 0.05 vs. vehicle control, **p < 0.05 vs. sorafenib, measured using  one-way ANOVA and Bonferroni posttest comparison. Error bars in some data points are smaller than the symbols